



Thomson Reuters and the National Foundation for Cancer Research Provide Online Help for Cancer Patients

April 22, 2009

NexCura Cancer Profiler Tools Provide Patients with Treatment Information on www.nfcr.org

ANN ARBOR, Mich., April 22 /PRNewswire/ -- The National Foundation for Cancer Research (NFCR) announced today that it will incorporate NexCura(R) Cancer Profiler Tools from Thomson Reuters into its Web site.

The 20 online tools will provide cancer patients with critical, customized information about their treatment options.

"We are excited to provide a unique service like this to patients dealing with the stresses and questions that come with the diagnosis of cancer," said Franklin C. Salisbury, Jr., president of NFCR. "These tools empower cancer patients with the information they need but can't always easily find. These patients are under enough stress without having to experience difficulty in finding the information they need."

Alicia Moffat, vice president of Web operations for the Healthcare business of Thomson Reuters, explains: "The tools were created using patented technology that guides users through a step-by-step questionnaire to match the patient's diagnosis, diagnostic results, and disease stage with the relevant treatment options." All information provided by the NexCura Cancer Profiler Tools is peer-reviewed.

NFCR offers the NexCura Cancer Profiler under the Treatment Decision Tools section of its Web site (<http://www.nfcr.org/patientsupport>). The NexCura Cancer Profiler is the only online service generating comprehensive treatment information that is personalized for specific diagnoses and clinical status. The customized information enables patients to better communicate with their doctors and care teams and, through education, encourages the patient to play a more proactive role in treatment decisions.

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.

About NFCR

The National Foundation for Cancer Research has supported cutting-edge cancer research to advance personalized medicine and targeted therapies for over three decades. As a leading cancer charity, NFCR is dedicated to funding scientists who are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the hope for curing cancer. NFCR brings the most advanced medical resources to oncologists and health professionals to help guide their treatment decisions for patients worldwide. For more information, visit www.nfcr.org.

SOURCE Thomson Reuters

-0-

04/22/2009

/CONTACT: David Wilkins, Media Relations, Healthcare, +1-734-913-3397,

david.wilkins@thomsonreuters.com/

/Web Site: <http://www.thomsonreuters.com> /

(TRI)

CO: Thomson Reuters; National Foundation for Cancer Research

ST: Michigan

IN: MTC HEA WEB CPR

SU: PDT

PR

-- DE03679 --

9979 04/22/2009 16:03 EDT <http://www.prnewswire.com>